- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 285/12 - 1,3,4-ThiadiazolesHydrogenated 1,3,4-thiadiazoles
Patent holdings for IPC class C07D 285/12
Total number of patents in this class: 201
10-year publication summary
16
|
16
|
17
|
10
|
5
|
4
|
6
|
7
|
1
|
7
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Array BioPharma Inc. | 503 |
9 |
Bristol-myers Squibb Company | 4872 |
7 |
Oryzon Genomics S.A. | 106 |
5 |
Reata Pharmaceuticals, Inc. | 123 |
5 |
Receptos LLC | 63 |
5 |
The Arizona Board of Regents on Behalf of the University of Arizona | 2147 |
4 |
The Lubrizol Corporation | 1284 |
4 |
Omeros Corporation | 307 |
4 |
Piramal Enterprises Limited | 154 |
4 |
PRAECIS Pharmaceuticals Incorporated | 17 |
4 |
Merck Sharp & Dohme LLC | 3753 |
4 |
Glaxo Group Limited | 4128 |
3 |
Sanofi-Aventis Deutschland GmbH | 2633 |
3 |
Board of Regents, The University of Texas System | 5760 |
3 |
KYORIN Pharmaceutical Co., Ltd. | 169 |
3 |
Ohio State Innovation Foundation | 2112 |
3 |
Proteostasis Therapeutics, Inc. | 70 |
3 |
PTC Therapeutics, Inc. | 483 |
3 |
Shionogi & Co., Ltd. | 860 |
3 |
Taisho Pharmaceutical Co., Ltd. | 869 |
3 |
Other owners | 119 |